Key Takeaways SOLV posted Q4 adjusted EPS of $1.57 on $1.99B revenue, topping consensus estimates.SOLV saw organic growth across MedSurg, Dental, and HIS, led by infection prevention and restoratives.SOLV's gross margin fell 270 bps, while adjusted operating income declined 5.9% year over year.Solventum (SOLV) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.57, which beat the Zacks Consensus Estimate of $1.50 by 4.7%. The bottom line improved 11.3% year over year.GAAP EPS in the quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION SOLVENTUM CORPORATION (Exact name of registrant as specified in its charter) Delaware 92-2008841 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 3M Center, Building 275-6W 2510 Conway Avenue East, Maplewood, Minnesota 55144 WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT P ...

For the quarter ended December 2025, Solventum (SOLV) reported revenue of $2 billion, down 3.7% over the same period last year. EPS came in at $1.57, compared to $1.41 in the year-ago quarter.The reported revenue represents a surprise of +1.57% over the Zacks Consensus Estimate of $1.97 billion. With the consensus EPS estimate being $1.50, the EPS surprise was +4.67%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

Solventum (SOLV) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.5 per share. This compares to earnings of $1.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.67%. A quarter ago, it was expected that this health care company would post earnings of $1.43 per share when it actually produced earnings of $1.5, delivering a surprise of +4.9%.Over the last four quarters, the compa ...

Solventum (NYSE:SOLV) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAmy Wakeham - Senior Vice President of Investor Relations and External Finance CommunicationsBryan Hanson - CEODavid Roman - Managing Director in Global Investment Research DivisionDylan Finley - Director in Equity ResearchRick Wise - Managing Director in Medical Technology and SuppliesTravis Steed - Director in Medical Technology Equity ResearchVik Chopra - Director in Medical Technology Equity ResearchWayde McMil ...

Solventum (NYSE:SOLV) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAmy Wakeham - Senior Vice President of Investor Relations and External Finance CommunicationsBryan Hanson - CEODavid Roman - Managing Director in Global Investment Research DivisionDylan Finley - Director in Equity ResearchLeah Keiser - Equity Research AssociateRick Wise - Managing Director in Medical Technology and SuppliesTravis Steed - Director in Medical Technology Equity ResearchWayde McMillan - CFOConference ...

Solventum (NYSE:SOLV) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker6Good afternoon. My name is Audra, and I will be your conference call operator today. I would like to welcome everyone to Solventum's fourth quarter 2025 earnings call. As a reminder, this conference is being recorded. All lines have been placed on mute to prevent any background noise. I would now like to turn the program over to your host for today's conference, Amy Wakeham, Senior Vice President of Investor Relations and Fina ...

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Solventum beats quarterly estimates on strong demand for surgical products February 26, 20269:43 PM UTCUpdated ago By Reuters Sign up here. Solventum's MedSurg business, which sells wound dressings and surgical equipment, accounts for more than half the company's revenue. Sales in the segment rose 5.2% from a year earlier to $1.24 billion during the quarter. The company's quarterly revenue cam ...

Q4 FY25 Earnings Presentation February 26, 2026 © Solventum 2026. All rights reserved. Forward-looking statements and use of document This presentation and other materials Solventum has filed or will file with the U.S. Securities & Exchange Commission ("SEC") (and oral communications that Solventum may make) contain forward-looking information about Solventum's financial results and estimates and business prospects, including guidance for 2026, that contain or incorporate by reference statements that relate ...

Exhibit 99.1 Organic sales growth in the quarter reflects positive performance from all segments, primarily driven by results of the Infection Prevention and Surgical Solutions business within MedSurg as well as Dental Solutions. GAAP and adjusted operating income margin remained largely consistent with prior year. On an adjusted basis, operating expense savings and the accretive benefit of the Purification and Filtration divestiture more than offset incremental tariff headwinds. Debt paydown following the ...